| Literature DB >> 33379066 |
Guangcheng Luo1, Jun Zhang2, Shun Zhang2, Bei Hu2, Lillian Hu3, Zhen Huang4.
Abstract
In detecting infectious diseases, such as coronavirus 2019 (COVID-19), real-time reverse-transcription polymerase chain reaction (RT-PCR) is one of the most important technologies for RNA detection and disease diagnosis. To achieve high quality assurance, appropriate positive and negative controls are critical for disease detection using RT-PCR kits. In this study, we have found that commercial kits often adopt DNAs instead of RNAs as the positive controls, which can't report the kit problems in reverse transcription, thereby increasing risk of the false negative results when testing patient samples. To face the challenge, we have proposed and developed the chemically modified RNAs, such as phosphoroselenaote and phosphorothioate RNAs (Se-RNA and S-RNA), as the controls. We have found that while demonstrating the high thermostability, biostability, chemostability and exclusivity (or specificity), both Se-RNA and S-RNA can be fine templates for reverse transcription, indicating their potentials as both positive and negative controls for RT-PCR kits.Entities:
Keywords: COVID-19; DNA- or RNA-Based positive and ngegative controls; Phosphoroselenaote RNA; Phosphorothioate RNA; RT-PCR
Year: 2020 PMID: 33379066 PMCID: PMC7657100 DOI: 10.1016/j.talanta.2020.121850
Source DB: PubMed Journal: Talanta ISSN: 0039-9140 Impact factor: 6.057
Fig. 1DNAs were chosen as positive controls in the commercial kits for COVID-19 detection. Figure A to F refer to six commercial RT-PCR kits. In each figure, positive and negative controls were from corresponding kit, respectively; Curve 1: RT-PCR with undigested positive control; Curve 2: RT-PCR with positive control digested with RNase A; Curve 3: RT-PCR with positive control digested with DNase I; Curve 4: negative control.
False negative detection of COVID-19 RNA with commercial kit.
| Kit/Sample | COVID-19 RNA sample 1 | COVID-19 RNA sample 2 | Positive control (from kit) | Negative control |
|---|---|---|---|---|
| >45 | >45 | 34.2 | >45 | |
| 23.5 | 26.1 | 33.6 | >45 | |
| 22.9 | 25.6 | 31.5 | >45 |
These experiments have been repeated for five times, and the results were consistent.
Fig. 2False negative results caused by the problematic commercial kit (Table 1). In each figure, Curve 1: COVID-19 positive RNA sample 1; Curve 2: COVID-19 positive RNA sample 2; Curve 3: positive control of corresponding kit; Curve 4: negative control of corresponding kit.
Fig. 3Bioactivity of Se-RNA and S-RNA. (A) Se-RNA and S-RNA transcription. Lane 1: DNA template; Lane 2: transcripted Se-RNA before DNase I digestion; Lane 3: transcripted Se-RNA after DNase I digestion; Lane 4: transcripted S-RNA before DNase I digestion; Lane 5: transcripted S-RNA after DNase I digestion. (B) Both Se-RNA and S-RNA can be efficiently recognized by MLV reverse transcriptase. Lane 1, FAM labeled primer; Lane 2: S-RNA was used as the template for cDNA reverse transcription; Lane 3: Se-RNA as the templale. (C) Se-RNA and S-RNA can be efficiently amplified and detected by RT-PCR.
Detection sensitivity of the canonical and modified RNAs.
| Template | 1000 copies | 500 | 100 | 50 |
|---|---|---|---|---|
| 31.2 | 33.5 | 35.8 | 36.0 | |
| 32.9 | 33.7 | 35.0 | 37.1 | |
| 32.5 | 33.9 | 34.5 | 36.4 |
Fig. 4Enhanced stability of Se-RNA and S-RNA. Figure A–C refer to the thermostability study of Se-RNA, S-RNA and O-RNA at room temperature, 55, 72 and 95 °C for 1 h, respectively. Figure D–F refer to the biostability study of Se-RNA, S-RNA and O-RNA with RNase-T1, serum and saliva, respectively. Figure G–I refer to the chemo-stability study of Se-RNA, S-RNA and O-RNA stored at 4 °C for 0–30 days, respectively.
Se-RNA and S-RNA as negative controls for RT-PCR.
| Negative Control | Primer Pair 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 |
|---|---|---|---|---|---|---|---|---|
| 35 | 35 | 40 | 34 | 33 | 39 | 41 | >45 | |
| 37 | 42 | >45 | 41 | 35 | >45 | >45 | >45 | |
| >45 | 44 | >45 | 36 | 37 | 40 | >45 | >45 |